TransThera Sciences (Nanjing)

TransThera Sciences (Nanjing), Inc. is a clinical-stage pharmaceutical company that discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. Its lead candidate, Tinengotinib (TT-00420), is a multi-kinase inhibitor in clinical development for recurrent or refractory drug-resistant solid tumors. The company also develops TT-00973, a kinase inhibitor for various cancers; TT-01488, a BTK inhibitor for B-cell lymphoma; TT-01688, an oral S1P1 modulator for inflammatory diseases; TT-00920, an oral PDE9 inhibitor for central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor for NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. It has collaborations with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple diseases and with Akeso, Inc. for the treatment of hepatocellular carcinoma. Formerly known as Nanjing TransThera Biosciences Co. Ltd., it changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.